Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were used:
mouse monoclonal anti-actin antibody,
anti-FLAG M2 antibody and HRP-conjugated
anti-FLAG M2 antibody (Sigma-Aldrich),
mouse monoclonal anti-RyR antibody 34C (Thermo Scientific, Rockford, IL, USA, or Developmental Studies Hybridoma Bank, University of Iowa, Iowa, USA) and mouse monoclonal anti-Bcl-X
L antibody YTH-2H12 (Trevigen, Gaithersburg, WV, USA). The sequences of the peptides used in this study were:
Biotin-BH4-Bcl-X
L: Biotin-MSQSNRELVVDFLSYKLSQKGYSW (also used without the biotin tag)
Biotin-scrambled BH4-Bcl-X
L: Biotin-WYSKQRSLSGLVMYVLEDKNSQFS
Control peptide: WYEKQRSLHGIMYYVIEDRNTKGYR
These peptides were synthesized by Life Tein (Hillsborough, NJ, USA) with a purity of at least 85%.
Vervliet T., Lemmens I., Vandermarliere E., Decrock E., Ivanova H., Monaco G., Sorrentino V., Kasri N.N., Missiaen L., Martens L., De Smedt H., Leybaert L., Parys J.B., Tavernier J, & Bultynck G. (2015). Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain. Scientific Reports, 5, 9641.